Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SORD | Q00796 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261284 | 0.78 | HTT (0.41) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL2053373 | 0.78 | KDM4E (0.45) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL5805673 | 0.78 | SMN1; SMN2 (0.36) | HTTTSHRSMN1; SMN2 | |
| SCHEMBL14334531 | 0.77 | KDM4E (0.40) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7220242 | 0.77 | TSHR (0.41) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL16125136 | 0.77 | KDM4E (0.37) | HTTKDM4EGAATSHRSORD | |
| SCHEMBL7221203 | 0.76 | KDM4E (0.39) | HTTKDM4EGAATSHR | |
| SCHEMBL13324127 | 0.74 | HTT (0.42) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL14333359 | 0.74 | SMN1; SMN2 (0.44) | HTTKDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL8142536 | 0.74 | TSHR (0.48) | HTTKDM4EGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-3348556-B1 | HETEROARYL AMIDES AS INHIBITORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2020-04-29 | — | — | EP | disclosed |
| US-10358443-B2 | Heteroaryl amides as inhibitors of protein aggregation | UCB BIOPHARMA SPRL (BE) | 2019-07-23 | — | — | US | disclosed |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | HTT 621/4885KDM4E 1910/4885GAA 670/4885 |
| US-10358443-B2 | Heteroaryl amides as inhibitors of protein aggregation | HTT, PARK7, UACA | HTT 1/4885KDM4E 1702/4885GAA 616/4885 |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | HTT 3246/4885KDM4E 2131/4885GAA 1927/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | HTT 681/4885KDM4E 1776/4885GAA 631/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | HTT 431/4885KDM4E 1088/4885GAA 1016/4885 |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | OPRK1, OPRL1, OPRD1 | HTT 2847/4885KDM4E 1674/4885GAA 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.